• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[双膦酸盐类药物治疗骨质疏松症及其他骨骼疾病]

[Bisphosphonate treatment of osteoporosis and other skeletal diseases].

作者信息

Syversen Unni, Halse Johan I

机构信息

Avdeling for endokrinologi, St. Olavs hospital, Trondheim.

出版信息

Tidsskr Nor Laegeforen. 2011 Feb 4;131(3):244-7. doi: 10.4045/tidsskr.09.0470.

DOI:10.4045/tidsskr.09.0470
PMID:21304573
Abstract

BACKGROUND

Bisphosphonates are antiresorptive drugs widely used to treat osteoporosis. They are also used to treat hereditary skeletal diseases with systemic or local defects, and as a supplement in treatment of cancer. This paper provides an overview of pharmacokinetics, mode of action, and clinical effects.

MATERIAL AND METHODS

Literature was retrieved through a non-systematic search in Pubmed/Medline.

RESULTS

Bisphosphonates are derivates of pyrophosphate which bind to hydroxyapatite with high affinity. Aminobisphosphonates inhibit an enzyme in the mevalonate pathway, thereby inducing apoptosis and inhibiting osteoclast activity. A reduced incidence of vertebral and hip fractures has been shown for alendronate, risedronate and zoledronate, while ibandronate has been shown to only reduce vertebral fracture. Reduced mortality was observed in a study where patients with recent hip fracture were treated with zoledronic acid. Intravenous bisphosphonates improve compliance and are relatively simple to use. Bisphosphonates reduce the risk for skeletal complications and bone pain in breast cancer, myelomatosis and prostate cancer. They are also effective in the treatment of Paget's disease and bone marrow edema. Gastrointestinal adverse effects are relatively frequent with peroral bisphosphonates, while acute phase reactions with influenza-like symptoms are common with intravenous bisphosphonates.

INTERPRETATION

Aminobisphoshonates are effective in the treatment of osteoporosis and in other bone diseases, and as an adjuvance in the treatment of cancer.

摘要

背景

双膦酸盐是广泛用于治疗骨质疏松症的抗吸收药物。它们还用于治疗具有全身或局部缺陷的遗传性骨骼疾病,并作为癌症治疗的补充药物。本文概述了其药代动力学、作用方式和临床效果。

材料与方法

通过在Pubmed/Medline中进行非系统检索获取文献。

结果

双膦酸盐是焦磷酸盐的衍生物,能与羟基磷灰石高亲和力结合。氨基双膦酸盐抑制甲羟戊酸途径中的一种酶,从而诱导细胞凋亡并抑制破骨细胞活性。阿仑膦酸盐、利塞膦酸盐和唑来膦酸盐已显示可降低椎体和髋部骨折的发生率,而伊班膦酸盐仅显示可降低椎体骨折发生率。在一项对近期髋部骨折患者用唑来膦酸治疗的研究中观察到死亡率降低。静脉注射双膦酸盐可提高依从性且使用相对简便。双膦酸盐可降低乳腺癌、骨髓瘤和前列腺癌患者发生骨骼并发症和骨痛的风险。它们在治疗佩吉特病和骨髓水肿方面也有效。口服双膦酸盐相对频繁地出现胃肠道不良反应,而静脉注射双膦酸盐常见类似流感症状的急性期反应。

解读

氨基双膦酸盐在治疗骨质疏松症和其他骨骼疾病以及作为癌症治疗的辅助药物方面有效。

相似文献

1
[Bisphosphonate treatment of osteoporosis and other skeletal diseases].[双膦酸盐类药物治疗骨质疏松症及其他骨骼疾病]
Tidsskr Nor Laegeforen. 2011 Feb 4;131(3):244-7. doi: 10.4045/tidsskr.09.0470.
2
Fracture risk associated with chronic use of bisphosphonates: evidence today.慢性使用双膦酸盐相关的骨折风险:现有证据。
Expert Opin Drug Saf. 2011 Jan;10(1):67-76. doi: 10.1517/14740338.2010.517192. Epub 2010 Dec 2.
3
Bisphosphonate treatment of pediatric bone disease.双膦酸盐治疗小儿骨病。
Pediatr Endocrinol Rev. 2005 Dec;3(2):87-96.
4
[The successful development of bisphosphonates in the therapy of osteoporosis].[双膦酸盐类药物在骨质疏松症治疗中的成功研发]
Med Klin (Munich). 2006 Jun;101 Suppl 1:6-14. doi: 10.1007/s00063-006-9002-x.
5
[Bisphosphonate].[双膦酸盐]
Nihon Rinsho. 2011 Jul;69(7):1253-7.
6
A once-yearly IV bisphosphonate for osteoporosis.一种用于治疗骨质疏松症的每年静脉注射一次的双膦酸盐药物。
Med Lett Drugs Ther. 2007 Nov 5;49(1273):89-90.
7
Bisphosphonate therapy and dental treatment.双膦酸盐治疗与牙科治疗
J Indiana Dent Assoc. 2007;86(4):4-8.
8
Bisphosphonates in the treatment of osteoporosis.双膦酸盐类药物在骨质疏松症治疗中的应用。
Endocrinol Metab Clin North Am. 2012 Sep;41(3):487-506. doi: 10.1016/j.ecl.2012.04.007. Epub 2012 Jun 9.
9
Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition.用于治疗骨病的双膦酸盐疗法:关于破骨细胞抑制的硬性和软性数据。
Mol Interv. 2010 Jun;10(3):141-52. doi: 10.1124/mi.10.3.5.
10
[Bisphosphonate].[双膦酸盐]
Nihon Rinsho. 2015 Oct;73(10):1683-9.

引用本文的文献

1
Efficacy and safety of bisphosphonates in pediatric glucocorticoid-induced osteoporosis: a meta-analysis and pharmacovigilance study.双膦酸盐类药物治疗儿童糖皮质激素性骨质疏松症的疗效与安全性:一项荟萃分析及药物警戒研究
Front Pediatr. 2025 Jul 7;13:1571381. doi: 10.3389/fped.2025.1571381. eCollection 2025.
2
Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1.氨膦酸盐会使 HIV-1 感染者的潜伏库重新激活。
Front Immunol. 2023 Sep 6;14:1219250. doi: 10.3389/fimmu.2023.1219250. eCollection 2023.
3
Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1.
氨基双膦酸盐可重新激活HIV-1感染者体内的潜伏病毒库。
bioRxiv. 2023 Feb 7:2023.02.07.527421. doi: 10.1101/2023.02.07.527421.
4
Relationship of knowledge about osteoporosis with education level and life habits.骨质疏松症知识与教育水平和生活习惯的关系。
World J Orthop. 2013 Jul 18;4(3):139-43. doi: 10.5312/wjo.v4.i3.139.